V
33.30
-0.21 (-0.63%)
| Previous Close | 33.51 |
| Open | 33.50 |
| Volume | 700,113 |
| Avg. Volume (3M) | 2,321,110 |
| Market Cap | 3,884,542,720 |
| Price / Book | 9.07 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2026 |
| Diluted EPS (TTM) | -1.54 |
| Total Debt/Equity (MRQ) | 0.11% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -152.54 M |
| Levered Free Cash Flow (TTM) | -102.10 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -19.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Viking Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
1.1
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 70.06% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIAN BRIAN | 33.86 | 33.43 | 73,150 | 2,540,721 |
| MANCINI MARIANNA | 33.86 | 33.43 | 13,450 | 463,250 |
| ZANTE GREG | 33.86 | 33.43 | 10,450 | 362,960 |
| Aggregate Net Quantity | 97,050 | |||
| Aggregate Net Value ($) | 3,366,932 | |||
| Aggregate Avg. Buy ($) | 33.86 | |||
| Aggregate Avg. Sell ($) | 33.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MANCINI MARIANNA | Officer | 29 Jul 2026 | Sell (-) | 18,217 | 33.43 | 608,994 |
| ZANTE GREG | Officer | 29 Jul 2026 | Sell (-) | 21,217 | 33.43 | 709,284 |
| LIAN BRIAN | Officer | 29 Jul 2026 | Sell (-) | 148,517 | 33.43 | 4,964,923 |
| MANCINI MARIANNA | Officer | 28 Jul 2026 | Acquired (+) | 31,667 | 33.86 | 1,072,245 |
| ZANTE GREG | Officer | 28 Jul 2026 | Acquired (+) | 31,667 | 33.86 | 1,072,245 |
| LIAN BRIAN | Officer | 28 Jul 2026 | Acquired (+) | 221,667 | 33.86 | 7,505,645 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |